Overview

Webcast ImageWebcast
Audentes Therapeutics Inc at 2018 Wedbush PacGrow Healthcare Conference (Replay)
08/14/18 at 1:55 p.m. ET
Audentes Therapeutics Inc at 2018 Wedbush PacGrow Healthcare Conference
Tuesday, August 14, 2018 1:55 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$33.04
Change (%) Stock is Down 0.34 (1.02%)
Volume151,674
Data as of 08/17/18 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $33.04 with a 52 week high of $46.18 and a 52 week low of $17.93.
Recent NewsMore >>
08/09/18
Audentes Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
08/07/18
Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
07/31/18
Audentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular Myopathy
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Andrew H. Chang
Director, Investor Relations
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.